Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Seek urgent medical care for severe abdominal pain, persistent vomiting, signs of pancreatitis, or intestinal obstruction
Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023
Further research is needed to better understand patient perspectives and support needs
The SCALE Obesity and Prediabetes trial showed Liraglutide 3mg led to an average body weight loss of around 8% after 56 weeks
Medicare helps cover the care
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study
US$ 22.42
US$ 23.86
US$ 28.80
US$ 21.49
US$ 29.52
US$ 22.40
US$ 26.56
US$ 22.78
US$ 26.10
